efficacy of diflunisal for hereditary transthyretin amyloidosis: data from the sveattr registry
Published 2 months ago • 37 plays • Length 0:46Download video MP4
Download video MP3
Similar videos
-
2:05
investigating the efficacy of tp-3654 in patients with myelofibrosis: results from phase i study
-
3:14
the impact of amyloid deposits in al amyloidosis
-
1:14
promising therapies under investigation in al amyloidosis: anti-fibril agents & bispecifics
-
1:27
insights into the reveal trial: the efficacy of ruxolitinib for the treatment of patients with pv
-
1:56
the efficacy of olutasidenib in patients with r/r idh-mutant aml
-
1:43
doxycycline/tudca versus standard supportive therapy in transthyretin cardiac amyloidosis
-
2:41
cell avidity as a predictor of t-cell efficacy
-
4:04
results of phase ii trial to assess the efficacy and safety of idelalisib
-
5:00
long-term results of the phase ii revive study evaluating rusfertide in patients with pv
-
4:35
updated safety & efficacy data from manifest-2: pelabresib plus ruxolitinib for myelofibrosis
-
2:00
the development of anti-fibrotic agents for treating myelofibrosis
-
1:52
safety and efficacy of idasanutlin in pv
-
2:34
ruby & edithal trials: evaluating the safety and efficacy of edit-301 in scd & thalassemia
-
7:30
updates from juliet: correlative analyses and clinical characteristics associated with efficacy
-
2:17
insights into the real-world efficacy of luspatercept in patients with lr-mds
-
1:39
the mechanism of action of navtemadlin and its role in mf
-
4:02
elm-2: promising safety and efficacy of odronextamab in r/r dlbcl
-
2:10
using the innate immune system to treat mds & the value of novel immunotherapies
-
1:56
incorporating novel agents for myelofibrosis in the pre- and post-transplant settings
-
1:09
the changing role of allosct in dlbcl in the era of novel agents
-
0:52
the need to incorporate disease-modifying drugs in lower-risk mds
-
2:41
an overview of the latest advances in hematology